Subscribe

Cecilia Gallo, MSN, AGNP-C, APRN, OCN

Lead Advanced Practice Provider
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, IL

Authored Items

The Role of the Oncology Nurse in an Era of Novel Therapies
By Cecilia Gallo, MSN, AGNP-C, APRN, OCN
Faculty Perspectives: PI3K Inhibitors: Efficacy in Hematologic Malignancies and Management of Treatment-Related Adverse Events - TON
The development and utilization of novel therapies, including small-molecule agents, have undoubtedly altered the treatment landscape for many indolent non-Hodgkin B-cell malignancies in the frontline and relapsed/ refractory settings. The availability of such agents as Bruton tyrosine kinase, BCL2, and phosphoinositide 3-kinase (PI3K) inhibitors addresses an unmet need among oncologists and advanced practice providers (APPs) who are seeking additional therapeutic options for their patients, particularly those with relapsed/refractory disease.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.